Alfuzosin hydrochloride

Product Name:    Alfuzosin hydrochloride

Synonyms:    Alfuzosin-d7 HCl;Alfuzosin hydrochlorid;Alfuzosin Hydrochloride (150 mg);Alfuzosin hydrochloride(Uroxatral);Uroxatral;Alfuzosin hydrocholoride;Uroxatral hydrochloride;N-(3-((4-Amino-6,7-dimethoxyquinazolin-2-yl)(methyl)amino)-propyl)tetrahydrofuran-2-carboxamid

CAS:    81403-68-1

MF:    C19H28ClN5O4

MW:    425.91

EINECS:    620-512-3

Product Categories:    Uroxatral;API;Antihypertensive, Treatment of BPH;Amines;Aromatics;Heterocycles;APIs;Antihypertensive;Intermediates & Fine Chemicals;Pharmaceuticals;Alfuzosin

Alfuzosin (SL-77499) (I), a quinazoline derivative which is a uroselective alpha-1 adrenoreceptor antagonist, has been developed and launched worldwide by Sanofi-Synthelabo, for the treatment of benign prostate hyperplasia (BPH). In November 2003, alfuzosin (I) was launched as an extended release formulation in the US as Uroxatral utilizing Skyepharma’s oral controlled release technology.